EC Approves Tecentriq Combination Therapy for Metastatic Triple-Negative Breast Cancer

September 3, 2019
Pharmaceutical Technology Editors

Roche revealed that the European Commission has approved the combination of Tecentriq (atezolizumab) with Abraxane for the treatment of adult patients with PD-L1-positive, metastatic triple-negative breast cancer.

In an Aug. 29, 2019 press release, Roche revealed that the European Commission (EC) has approved the combination of Tecentriq (atezolizumab) with Abraxane for the treatment of adult patients with PD-L1-positive, metastatic triple-negative breast cancer.

This approval was based on Phase III Impassion 130 study, which demonstrated that the combination therapy was capable of improving outcomes of patients with PD-L1-positive metastatic triple-negative breast cancer. As a result of the approval by the EC, Tecentriq combination has become the first cancer immunotherapy regimen available for treatment of triple-negative breast cancer in Europe.

“For the past 30 years, we have been dedicated to transforming the lives of people with breast cancer. Now, we are pleased to build on this foundation with the news that the first immunotherapy treatment for triple-negative breast cancer is available to people in Europe with PD-L1-positive, metastatic triple-negative breast cancer,” said Sandra Horning, Roche’s chief medical officer and head of Global Product Development, in the press release. “The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great.”

Source: Roche